Phase I and pharmacologic study of the combination paclitaxel and carboplatin as first-line chemotherapy in stage III and IV ovarian cancer

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
M T HuizingW W ten Bokkel Huinink

Abstract

To determine the maximum-tolerated dose for the combination paclitaxel and carboplatin administered every 4 weeks and to gain more insight into the pharmacokinetics and pharmacodynamics of this combination in previously untreated ovarian cancer patients. Thirty-five chemotherapy-naive patients with suboptimally debulked stage III (tumor masses > 3 cm) and stage IV ovarian cancer were entered onto this phase I trial in which paclitaxel was administered as a 3-hour intravenous (IV) infusion at dosages of 125 to 225 mg/m2 immediately followed by carboplatin over 30 minutes at dosages of 300 to 600 mg/m2. A total of six courses was planned, followed by a second-look laparoscopy/laparotomy. Patients with a response and/or minimal residual disease at second-look laparoscopy received three additional courses. Twenty-six patients participated in the pharmacokinetic part of the study. The most important hematologic toxicity encountered was neutropenia. Neutropenia was more pronounced for the higher dose levels (DLs) and was cumulative. Thrombocytopenia was mild in the first eight DLs, but increased during the treatment courses. Nonhematologic toxicities consisted mainly of vomiting, neuropathy, fatigue, rash, pruritus, myalgia, and arth...Continue Reading

Citations

Dec 11, 2002·Expert Opinion on Pharmacotherapy·Sakkaraiappan Ramalingam, Chandra P Belani
Oct 17, 2019·Pharmaceutical Research·Marie-Rose B S CrombagAlwin D R Huitema
Jul 7, 2000·Seminars in Surgical Oncology·D E MarsdenN F Hacker
Feb 7, 2001·Cancer Investigation·D KhayatD Coeffic
Mar 10, 2001·International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society·P. G. RoseM. Rodriguez
Jun 11, 2017·The Journal of Pharmacology and Experimental Therapeutics·Andrea HenrichZinnia Patricia Parra-Guillen
Mar 4, 1998·Current Opinion in Obstetrics & Gynecology·L M Chen, J S Berek
Oct 31, 2000·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·A PatnaikA M Oza
Mar 17, 2007·International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society·A L LeiserC Aghajanian
Nov 21, 2000·Drug Safety : an International Journal of Medical Toxicology and Drug Experience·L B MichaudG Hortobagyi
May 31, 2002·Expert Opinion on Pharmacotherapy·Tarek M Mekhail, Maurie Markman
May 23, 2006·Pharmaceutical Research·Danny ChenJessie L-S Au
Nov 8, 2008·Cancer Chemotherapy and Pharmacology·Corine EkhartAlwin D R Huitema
Jun 15, 2017·Clinical Pharmacokinetics·Tore B StageDeanna L Kroetz
Jan 9, 2019·Pharmaceutical Research·Marie-Rose B S CrombagAlwin D R Huitema
Sep 14, 2002·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·David LoeschEdwin Cox
Nov 7, 2006·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Corine EkhartJos H Beijnen
Oct 6, 2005·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Udai BanerjiPaul Workman
Dec 5, 2000·European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences·J H SchellensJ H Beijnen

❮ Previous
Next ❯

Related Concepts

Related Feeds

Anemia

Anemia develops when your blood lacks enough healthy red blood cells. Anemia of inflammation (AI, also called anemia of chronic disease) is a common, typically normocytic, normochromic anemia that is caused by an underlying inflammatory disease. Here is the latest research on anemia.

Related Papers

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
C AghajanianD R Spriggs
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
Marco B PoleeAte van der Gaast
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
H C PitotC Erlichman
© 2021 Meta ULC. All rights reserved